Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881504 · ClinicalTrials.gov registry record · Phase 2
A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00881504 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 9 participants.
The verdict
NCT00881504, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is for patients with biliary tract cancer that has spread and who are not candidates for surgical resection. The purpose of this research is to determine if bevacizumab can be safely administered with Modified FOLFOX 6 and find out what effects, good and/or bad, this type of treatment has on biliary cancer. In this study, a combination of chemotherapy, Modified FOLFOX6 and a biologic agent, bevacizumab will be tested. Subjects on this study will receive chemotherapy and bevacizumab every 2 weeks until their disease gets worse or they are unable to tolerate treatment.
Interventions
- DRUG "Bevacizumab" in combination with "modified FOLFOX6".
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881504
The ClinicalTrials.gov registry entry for NCT00881504 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which "Bevacizumab" in combination with "modified FOLFOX6". is the first listed.
NCT00881504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00881504 about?
NCT00881504 is a clinical study titled "A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma". This study is for patients with biliary tract cancer that has spread and who are not candidates for surgical resection. The purpose of this research is to determine if bevacizumab can be safely administered with Modified FOLFOX 6 and find out what effects, good and/or bad, this type of treatment ha...
What is the current status of trial NCT00881504?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2009-06. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00881504?
The interventions under investigation include: "Bevacizumab" in combination with "modified FOLFOX6". (DRUG).
Who is sponsoring clinical trial NCT00881504?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.